UK medicines agency wants feedback on information for patients site
This article was originally published in Scrip
The UK's medicines agency, the MHRA, has commissioned an online discussion site to consult on whether it should make its database of patient information leaflets and Summaries of Product Characteristics (SmPCs) available to the public via the internet.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.